Approval of esketamine for treatment-resistant depression – Authors' reply
Open accessIntegrity signals
Registry
Cites
Statistics
Claims the paper makes
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The text we found for this paper looks like another document, so the self-check wasn’t run.
Cites
Popova, V., Daly, E. J., Trivedi, M., Cooper, K., Lane, R., Lim, P., Mazzucco, C., Hough, D., Thase, M. E., Shelton, R. C., et al. (2019) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2019.19020172 · Cited by 904 · see citing works
Fedgchin, M., Trivedi, M., Daly, E. J., Melkote, R., Lane, R., Lim, P., Vitagliano, D., Blier, P., Fava, M., Liebowitz, M., et al. (2019) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyz039 · Cited by 606 · see citing works
Ochs-Ross, R., Daly, E. J., Zhang, Y., Lane, R., Lim, P., Morrison, R. L., Hough, D., Manji, H., Drevets, W. C., Sanacora, G., et al. (2020) · The American Journal of Geriatric Psychiatry · doi:10.1016/j.jagp.2019.10.008 · Cited by 481 · see citing works
Duru, G., & Fantino, B. (2008) · Current Medical Research and Opinion · doi:10.1185/030079908x291958 · Cited by 112 · see citing works
Leucht, S., Fennema, H., Engel, R. R., Kaspers–Janssen, M., Lepping, P., & Szegedi, A. (2016) · Journal of Affective Disorders · doi:10.1016/j.jad.2016.12.041 · Cited by 87 · see citing works
Esketamine for treatment resistant depression: a trick of smoke and mirrors?
Gastaldon, C., Papola, D., Ostuzzi, G., & Barbui, C. (2020) · Epidemiology and Psychiatric Sciences · doi:10.1017/s2045796019000751 · Cited by 54 · see citing works
Approval of esketamine for treatment-resistant depression
Singh, J. B., Daly, E. J., Mathews, M., Fedgchin, M., Popova, V., Hough, D., & Drevets, W. C. (2020) · The Lancet Psychiatry · doi:10.1016/s2215-0366(19)30533-4 · Cited by 46 · see citing works
Flagged first, then by citations
Research works printed but not linked: 2
- Cristea IA, Naudet F. US Food and Drug Administration approval of esketamine and brexanolone. Lancet Psychiatry 2019; 6: 975-77.
- Singh JB, Daly EJ, Mathews M, et al. Approval of esketamine for treatmentresistant depression. Lancet Psychiatry 2020; 7: 232-34.
Cited by
Sorted by citations
Gastaldon, C., Raschi, E., Kane, J. M., Barbui, C., & Schoretsanitis, G. (2021) · Psychotherapy and Psychosomatics · doi:10.1159/000510703 · Cited by 134 · see citing works
Orphan G Protein Coupled Receptors in Affective Disorders
Watkins, L. R., & Orlandi, C. (2020) · Genes · doi:10.3390/genes11060694 · Cited by 67 · see citing works
Baudot, J., Soeiro, T., Tambon, M., Navarro, N., Veyrac, G., Mezaache, S., & Micallef, J. (2021) · Fundamental and Clinical Pharmacology · doi:10.1111/fcp.12745 · Cited by 25 · see citing works
Erhel, F., Scanff, A., & Naudet, F. (2020) · Epidemiology and Psychiatric Sciences · doi:10.1017/s2045796020000359 · Cited by 19 · see citing works
Self-citationWłodarczyk, A., Dywel, A., & Cubała, W. J. (2023) · Pharmaceuticals · doi:10.3390/ph16020173 · Cited by 10 · see citing works
Naudet, F., Pellen, C., Fodor, L. A., Gastaldon, C., Barbui, C., Turner, E. H., Le Pabic, E., & Cristea, I. A. (2025) · BMC Medicine · doi:10.1186/s12916-025-04435-x · Cited by 6 · see citing works
“For the primary outcome, mean differences in MADRS scores observed (point estimates and confidence intervals was compared with 0 (absence of difference) and 6.5 points (the threshold defined a priori in initiation studies [6]).”
InfluentialSelf-citationEsketamine clinical trials: reply to Maju et al.
Gastaldon, C., Papola, D., Ostuzzi, G., & Barbui, C. (2020) · Epidemiology and Psychiatric Sciences · doi:10.1017/s204579602000027x · Cited by 6 · see citing works
- Authors
- Naudet, F., & Cristea, I. A.
- Affiliations
- Inserm (FR)
- University of Pavia (IT)
- Corresponding author
- Cristea, Ioana A
- Venue
- The Lancet Psychiatry
- Publisher
- Elsevier BV
- Published
- 2020-03
- Volume
- 7
- Issue
- 3
- Pages
- 235-236
- ISSN
- 2215-0366 (ISSN-L)
- OpenAlex
- W3008491249
- Cited by
- 7
- References
- 7
- Citations by year
- 2025: 1 · 2023: 1 · 2021: 1 · 2020: 4
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- The Lancet Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- HAL (submittedVersion, other-oa)
- Padua Research Archive (University of Padova) (submittedVersion)
- Padua Research Archive (University of Padova) (submittedVersion, cc-by-nc-nd)
- Topics
- Health Sciences › Medicine › Pharmacology › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
- Physical Sciences › Mathematics › Statistics and Probability › Statistical Methods in Clinical Trials
- Keywords
- esketamine, treatment-resistant depression, regulatory approval, minimal clinically important difference, Montgomery-Asberg Depression Rating Scale, significance testing, sample size determination, clinical trial endpoints, European Medicines Agency
- MeSH terms
- Depression, Humans, Ketamine, Depressive Disorder, Treatment-Resistant
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
